University Hospitals Birmingham NHS Foundation Trust

Loading results...
View full results list

Medicines A–Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

R

Status	Drug name	NICE TAs	Comments
	Risendronate tablets
	Risperidone injection		APC verdict - present status = RED (Future status = AMBER with a framework in primary care before transfer - commissioning discussion)
	Risperidone liquid		ESCA
	Risperidone tablets		ESCA
	Ritlecitinib	TA958 - Ritlecitinib for treating severe alopecia areata in people 12 years and over
	Ritumixab infusion (Mabthera®, Truxima®)	TA195 - Drugs for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
	Rituximab	TA243 - Rituximab for the first-line treatment of stage III-IV follicular lymphoma TA193 - Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia TA174 - Rituximab for the first-line treatment of chronic lymphocytic leukaemia TA137 - Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma TA65 - Rituximab for aggressive non-Hodgkin's lymphoma TA195 - Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor TA308 - Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis TA226 - Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma
	Rivaroxaban tablets	TA170 - Venous thromboembolism - Rivaroxaban TA335 - Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome TA256 - Atrial fibrillation (stroke prevention) - Rivaroxaban TA261 - Venous thromboembolism (treatment and long-term secondary prevention) - Rivaroxaban TA287 - Pulmonary embolism and recurrent venous thromboembolism TA607 - Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease	Amber - specialist initation following diagnosis of AF- use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants Amber - specialist initation for the treatment and secondary prevention of DVT and/or PE - use in line with NICE. Initiation/ recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD Amber - specialist initiation for preventing adverse outcomes after acute management of ACS use in line with NICE TA335. Initiation/recommendation by a clinician who routinely initiates anticoagulants. Where this is not the patient's GP, transfer to GP should be with the support of RICaD
	Rivaroxaban tablets #2.8	TA170 - Venous thromboembolism - Rivaroxaban TA607 - Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease	BSSE APC preferred agent. This recommendation must only be taken into account after a patient and prescriber have discussed all treatment options (including warfarin) and only if they have no preference about which medicine they want to use. Red use following hip and knee surgery – full course of treatment supplied on discharge
	Rivastigmine capsules	TA217 - Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease	Dementia drugs ESCA

Building healthier lives